Michel C, Courdavault L, al Khayat R, Viron B, Roux P, Mignon F
Service de Néphrologie, Hôpital Tenon, Paris, France.
Am J Nephrol. 1994;14(2):113-20. doi: 10.1159/000168699.
Fungal peritonitis (FP) is a serious complication of peritoneal dialysis, both in terms of morbidity and mortality. Available data on the effectiveness of fluconazole in eradicating FP without catheter removal are still controversial. We reviewed 20 FP cases that occurred among 325 patients who underwent peritoneal dialysis in our center between January 1984 and January 1992, in order to establish whether a profile of patients at risk of developing FP could be identified and to evaluate the effectiveness of fluconazole in treating FP (7 cases). Age, sex, a particular cause of end-stage renal disease, and the presence of diabetes did not correlate significantly with the development of FP. The risk of FP increased in patients on immunosuppressive treatment. Sixteen of our 20 patients had bacterial peritonitis during the month before they developed FP. Nineteen were treated with antibiotics. Neither the type of bacterial organism isolated during the bacterial peritonitis preceding FP nor modality and duration of antibiotic treatment correlated significantly with the development of FP. Patients who subsequently developed FP were more frequently treated with antibiotics while in hospital (p < 0.001). Candida species accounted for 15 of our 20 FP cases (75%), with Candida albicans being by far the most common isolate. Treatment strategies varied among the 20 patients. The combination of intravenous or intraperitoneal administration of 5-fluorocytosine and oral administration of fluconazole was used in 7 cases: only 1 patient was cured without catheter removal, 1 patient died within the first 4 days of treatment, removal of peritoneal catheter was necessary in the other 5 patients.(ABSTRACT TRUNCATED AT 250 WORDS)
真菌性腹膜炎(FP)是腹膜透析的一种严重并发症,无论在发病率还是死亡率方面都是如此。关于氟康唑在不拔除导管的情况下根除FP有效性的现有数据仍存在争议。我们回顾了1984年1月至1992年1月在我们中心接受腹膜透析的325例患者中发生的20例FP病例,以确定是否可以识别出有发生FP风险的患者特征,并评估氟康唑治疗FP(7例)的有效性。年龄、性别、终末期肾病的特定病因以及糖尿病的存在与FP的发生均无显著相关性。接受免疫抑制治疗的患者发生FP的风险增加。我们的20例患者中有16例在发生FP前一个月患有细菌性腹膜炎。19例接受了抗生素治疗。FP发生前细菌性腹膜炎期间分离出的细菌种类以及抗生素治疗的方式和持续时间与FP的发生均无显著相关性。随后发生FP的患者在住院期间更频繁地接受抗生素治疗(p<0.001)。念珠菌属占我们20例FP病例中的15例(75%),其中白色念珠菌是迄今为止最常见的分离菌株。20例患者的治疗策略各不相同。7例患者采用静脉或腹腔注射5-氟胞嘧啶与口服氟康唑联合治疗:仅1例患者在不拔除导管的情况下治愈,1例患者在治疗的前4天内死亡,其他5例患者需要拔除腹膜导管。(摘要截断于250字)